2025-05-29-Jefferies-杰富瑞生物科技红毯会议电话_峰会_非交易路演_晚宴及更多活动_9页_101kb

Equity Research Report Summary

Overview

This report provides an update on Jefferies' biotechnology equity research, highlighting upcoming events for institutional investors, analyst insights, company valuations, and key risks.

Upcoming Events and Meetings

• Conferences & Dinners:
  • Jefferies Global NYC HC Conference Biopharma Keynote Sessions on June 3-5, featuring panels on cell therapy, FDA perspectives, and M&A.
  • Biopharma Group Dinners on June 3-4, including companies like RYTM, CNTA, GILD, and others.
  • Corporate access events: Europe NDRs for ZLAB and KRYS, a Virtual NDR for RAPP.
• Conference Calls & Discussions:
  • "Generative AI in Biotech & Precision Medicine" event on May 30.
  • KOL Group Dinners at ASCO focusing on breast cancer, pancreatic/lung cancer, hematology, and HNSCC.
• Expert Replays:
  • Recent webinars on topics like Alzheimer's research, tariff implications, and company earnings previews.

Analyst Information and Certifications

• Analysts Featured: Michael J. Yee, Dina Elmonshed, Kyle Yang (CFA), Matthew Hagood, Madeleine Lee, and others.
• Certification Highlights: All analysts certify personal views reflect their opinions on companies, with no compensation tied to specific recommendations.

Investment Focus and Ratings

• Buy-Rated Companies: A selection of biotech firms, including Apogee Therapeutics (APGE), BioNTech (BNTX), Centessa (CNTA), and others. Ratings are based on valuation models including DCF, EV/EBITDA, and growth potential.

Key Risks and Disclosures

• Investment Risks: Total return expectations vary by rating (e.g., Buy aims for 15-20% returns). Market volatility, currency risks, and regulatory changes may affect performance.
• Conflicts of Interest: Jefferies has financial relationships with companies discussed, including underwriting services and market-making.
• Legal Compliance: Disclosures cover reporting standards, jurisdictional regulations, and non-distribution policies.

For detailed information, refer to pages 3–9 of the full report.